Introduction
TGFb1 is a multifunctional cytokine. However, there are three fundamental directions of its activities: I. it regulates cell proliferation, growth, differentiation, and cells movement; II. has immunomodulatory effects; and III. has profibrogenic effects. TGFb1 action can be local and systemic [1, 2] . It is an endogenous factor controlling apoptosis in normal and pathological tissues and thereby is a factor controlling the balance between replication and cell death [1, 3] . Lack of TGFb1-dependent growth control may result in oncogenesis. In normal conditions, TGFb1 is a potent inhibitor of the growth of many cell types, including neoplastic [1, 4] . In the early stages of cancer development, its cells respond to antimitotic effect of TGFb1 [1, 5] . However, at the entry of tumour cells into the phase of uncontrollable growth, most of them lose sensitivity to the inhibitory effect of TGFb1. What is more, these cancer cells begin to secrete TGFb1 themselves [1, 4] . The TGFb1-dependent immunosuppressive activity and stimulating angiogenesis [4] [5] [6] [7] creates a microenvironment favourable to tumour growth and its metastasis [1, 5] . TGFb1 induces the death of the surrounding healthy cells and thus eliminates their effect designed to inhibit tumour growth [1, 3] . The results of clinical and experimental studies indicate that the molecular reasons for the lack of cell response to TGFb1 during malignant transformation is caused by mutation in the TGFbRII receptor [8] . TGFb1 was immunosuppressive in patients with Graves' disease. It inhibited the proliferation of peripheral blood mononuclear cells and of peripheral and thyroid-derived T-cell lines and clones in response to non-specific stimuli. It also suppressed the recognition of thyroid epithelial cells by thyroid autoantigen specific T-cell clones. TGFb1 may exert a variety of down-regulatory influences in Graves' disease. It may be of importance for the suppression of autoaggression in persons predisposed to autoimmunity; it may be quantitatively overrun by immunostimulatory influences in the acute phase of the disease; and it may be important for the induction of remission in patients with Graves' disease [9, 10] . Triiodothyronine, through binding to its nuclear receptors (TRs), is able to antagonise transcriptional activation by TGFb/SMAD. This antagonism involves reduced phosphorylation of SMADs. T3 reduces occupancy of SMAD-binding elements in response to TGFb, reducing histone acetylation and inhibiting transcription [11] .
The principle of the study was the determination of gene-candidates' profile expression responsible for immunosuppression, angiogenesis, neoplasia, and fibrosis processes in the pathogenesis of thyroid gland disease. The objective of the study was to investigate the transcriptional activity of TGFb1 and its receptor (TGFbRI, TGFbRII, TGFbRIII) genes in diseased thyroid tissue in conjunction with the assessment of TGFb1 concentration in the blood.
Material and methods
The research was approved by the Ethical Committee of the Medical University of Silesia and was carried out in [2002] [2003] [2004] [2005] [2006] [2007] . Studies were performed altogether on 63 patients (48 females, 15 males, mean age: 42.3 years): in eight patients undergoing a near total thyroidectomy due to hyperthyreosis in the course of Graves' disease (GD) and in 55 patients undergoing subtotal or total thyroidectomy due to tuberous changes. In the latter group, patients were divided into groups in dependence on histopathological diagnosis of change in thyroid gland (neoplastic change, benign change) and on hormonal status: the group with papillary cancer (PTC) consisted of six patients, with non-toxic nodular goitre (NG) -27 patients, and with toxic nodular goitre (TNG) -22 patients. After thyroidectomy each thyroid specimen was immediately frozen in liquid nitrogen and stored at -80 0 C until it was used for RNA extraction. Paraffin-embedded thyroid specimens were histologically evaluated. Molecular analysis was performed in thyroid tissue derived from patients with Graves' disease (group GD) and in tissue derived from tumour centre (groups PTC, NG, TNG) and from peripheral parts of the removed lobe without histopathological lesions (tissue control -C). Control tissue (C) for analysis performed in GD was an unchanged thyroid tissue derived from peripheral parts of removed lobe of patients surgically treated for a single benign tumour. In study groups, blood was collected at four points during the day (at 7 am, 1 pm, 7 pm, and 1 am) to determine the presence of a possible circadian rhythm of TGFb1 and the calculation of its Mean Daily Concentrations (MDC) in the blood. Obtained sera were stored at -80°C until testing. In all those examined, the current endocrinological status was defined on the basis of thyroid gland ultrasound (USG), fine-needle aspiration biopsy (FNAB), serum levels of TSH (thyrotropin), fT4 (free thyroxin), eventually fT3 (free triiodothyronine), TSH receptor antibodies (TRAb), and anti-thyroid peroxidase antibodies (TPOAb). The control group (H) for estimation of TGFb1 MDC consisted of 20 healthy volunteers age-and sex-matched to diseased groups. The creation of the control group of healthy people composed from women and men was preceded in our previous study by a comparative analysis of the point concentrations of TGFb1 in the blood of women (n = 31) and the concentrations of TGFb1 in the blood of men (n = 28) [10] .
PRACE ORYGINALNE

Analysis in blood
Serum levels of TGFb1 were measured by an enzymelinked immunosorbent assay (ELISA) method using Quantikine Immunoassay (R&D Systems, USA) kits. Tests were performed in the Department of Pathophysiology and Endocrinology with a Universal Microplate Spectrophotometer -μQUANT (BIOTEK INC). The sensitivity of the method was < 7 pg/mL, intra-assay error and inter-assay error were, respectively, 4.9% and 10.3%. TRAb and TPOAb were estimated, respectively, by a radioimmune assay (RIA) method and the ELISA method. Serum levels of TSH and free thyroid hormones were assayed immunoenzymatically (MEIA) by routine laboratory techniques.
Molecular analysis in tissue
The expression of mRNA TGFb1 system subunits (TGFb1 and its receptors TGFbRI, TGFbRII, TGFbRIII) in thyroid tissue specimens were evaluated by Reverse Transcriptase Quantitative Polymerase Chain Reaction (RT-qPCR) with GAPDH as an indirect marker of tissue integrity.
RNA extraction from tissue specimens
Total RNA was isolated from the specimens applying commercially available kits (Total RNA Prep Plus A&A Biotechnology; Poland) according to manufacturer 's instruction based on the modification of the method of Chomczynski and Sacchi [12] . Quality of extracts was checked electrophoretically using 0.8% agarose gel stained with ethidium bromide. The results were analysed and registered using gel documentation system 1D Bas-Sys (Biotech-Fisher). In the case of RNA extracts contaminated by genomic DNA, the latter was removed by DNAase I (MBI Fermentas) according to the manufacturer's instruction. The concentration of total RNA was determined by spectrophotometric measurement in 5-mL capillaries using a Gene Quant II RNA/DNA Calculator (Pharmacia Biotech) making an assumption that the result of 1 OD, measured in a 10-mm light path cuvette, is equivalent to the concentration of 40 mg/cm 3 RNA extract.
Design of specific primers and probes used in the RT-qPCR reaction
Based on the data previously published in the Internet database GenBank (http://www.ncbi.nlm.nih.gov/irx/ /genbank) describing mRNA sequences for studied genes, we designed specific primers and probes for mRNA of these genes using the computer program Primer Express TM Version 1.0 ABI PRISM (Table I) . Both primers as well as the probe were synthesized in the Oligo IBB PAN (Poland). The TaqMan probe consists of an oligonucleotide with a 5´-reporter dye and a downstream, 3´-quencher dye. The fluorescent reporter dye, such as FAM (6-carboxy-fluorescein), is covalently linked to the 5´ end of the oligonucleotide. Each of the reporters is quenched by TAMRA (6-carboxy-tetramethyl-rhodamine), typically located at the 3´ end. When the probe is intact, the proximity of the reporter dye to the quencher dye results in suppression of the reporter fluorescence. , and under 100 ng total RNA. The optimum concentrations of probes and primers were determined -see Table II . ABI PRISM™ 7700 (TaqMan) sequence detector purchased from Applied Biosystems Co. was used to perform RT-qPCR reaction. RT-qPCR assay was performed in triplicate for each sample. Cycling conditions were as follows: one step at 60°C for 30 minutes, one step at 95°C for 5 minutes, 50 cycles at 95°C for 30 seconds, and 60°C for 1 minute and one step at 72°C for 10 minutes. The hybridisation probe was labelled with a reporter fluorescent dye (FAM) at the 5' end and a quencher fluorescent dye (TAMRA) at the 3' end. When this probe was placed in the PCR, the DNA polymerase that catalyses the PCR also cuts off any probe that specifically binds to template. The nucleolytic degradation of the hybridisation probe releases the quenching of FAM fluorescence emission. The higher the starting copy number of the mRNA target, the earlier the significant increase in fluorescence is observed.
Glyceraldehydre-3-phosphate dehydrogenase (GAPDH) was used as internal control in all individuals RT-qPCR for all samples. Gene expression of GAPDH was analysed using specific sequence primers and probe (Table III) .
On the basis the standard curve of each analysis was drawn and then an ABI PRISM™ 7700 sequence detector calculated the number of mRNA copies of the examined gene in analysed samples. RT-PCR products were run on 6% polyacrylamide gels and visualised with silver salts. To further confirm the product identity, they were sequenced with a BigDye Terminator V2.0 Cycle Sequencing Kit (Applied Biosystems, USA) using an automated sequencer (ABI PRISM TM 310 Genetic Analyzer, Applied Biosystems, USA).
Statistical analysis
Results were subjected to routine statistical analysis using the program Statistica, with significance level set at p < 0.05. For each quantitative parameter, basic statistical characteristics were made -mean, SD (standard deviation), SEM (standard error of the mean), minimal and maximal value, median, quartiles 25% and 75%, and 95% confidence interval. Chronobiological parameter estimation was performed using the cosinor method [Model: M+A*cos((Pi/12)*T+fi)]. Homogeneity of variance was checked by Fischer test. U Mann-Whitney's non-parametric rank sum test was applied where appropriate. For the assessment of intergroup correlations, a Spearman Rank Correlation test was used.
Results
Performing quantitative analysis of mRNA TGFb1 and its receptors TGFbRI-III in thyroid tissue obtained from patients with papillary cancer (PTC), non-toxic nodular goitre (NG), toxic nodular goitre (TG), and Graves' disease (GD) has shown no difference in expression of the TGFb1 system subunits between diseased and control tissues in all studied groups of patients (Table IV) . However, strict regulation observed among transcriptional activity of TGFb1 and their receptors TGFbRI-III genes in control tissues is disturbed in all pathological tissues -it is completely disturbed in PTC and GD, and partially in NG and TNG (Table IV) . Additionally, higher transcriptional activity of TGFb1 gene in PTC tissue in comparison with benign tissue (NG, GD) and lower expression of mRNA TGFbRII (than in TNG, GD) and mRNA TGFbRIII than in all studied benign tissues (NG, TNG, GD) suggest pathogenetic importance of this cytokine and its receptors in PTC development. In GD tissue, higher transcriptional activity of TGFbRII and TGFbRIII genes as compared to other pathological tissues was observed indicating participation of the receptors in the pathomechanism of autoimmune thyroid disease (AITD) ( Table V) . Substantially, we did not observe differences in serum TGFb1 concentrations between the studied groups; only in TNG patients was the cytokine level slightly decreased as compared to healthy controls (Table VI) . TGFb1 blood concentrations rather do not reflect the pathological processes taking place in thyroid gland, although in patients with TNG we noted a correlation between TGFb1 concentration in blood and mRNA TGFbRII expression in thyroid (Spearman's correlation coefficient (R) = -0.4257; p = 0.0482), which probably indicates the participation of circulating TGFb1 in the phenomenon of the receptor downregulation. No circadian rhythms of TGFb1 in all studied groups were found. No significant correlation was found between fT4, fT3, and measured TGFb1 system subunits expression. We also did not find any correlation between the TGFb1 system subunits expression and parameters of autoimmune thyroid disease, like TRAb or TPOAb.
Discussion
This study is the first report concerning the simultaneous quantitative analysis (RT-qPCR) of transcriptional activity of TGFb1 and its receptor (TGFbRI, TGFbRII, TGFbRIII) genes in thyroid tissue. The tissues derived from surgically treated patients with papillary cancer, nodular goitre (non-toxic and toxic), and Graves' disease. In recent years, occasionally TGFb1 mRNA expression in thyroid tissue was estimated by RT-PCR [18] . Brace et al. (2014) demonstrated, using RT-qPCR, that expression of TGFb1 but not of TGFb2 is increased in papillary cancer tissue compared to benign nodule tissue [19] . Most reports describing TGFb1 in thyroid gland diseases are based on assay of this factor in blood [10] or on qualitative or semi-quantitative but not quantitative analysis of TGFb1 expression in thyroid tissue [20] [21] [22] [23] . Immunohistochemical analyses of resection thyroid showed that the expressions of TGFb1 in thyroid cancers (papillary, follicular) were higher than in other benign thyroid lesions and normal thyroid tissues. In the study nodular goitre and Graves' disease tissues were also analysed [23] . The other immunohistochemical studies examining the role of TGFb in human thyroid tissues revealed increased cytoplasmic presence of TGFb at the periphery of poorly circumscribed PTC. These tumours were associated with increased invasiveness and metastasis with an increased propensity towards epithelial to mesenchymal transition [20, 21, 22] . In PTC cell lines and animal models, TGFb signalling has been shown to regulate cellular epithelial to mesenchymal transition [19, 20, 22, 25] . In thyroid PTC 
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cell lines, TGFb1 treatment was associated with the development more aggressive papillary cancer [24] . Overexpression of TGFb1 in thyroid tissue is associated with the occurrence of thyroid cancer, which can be used as a candidate for the diagnosis and prognosis of thyroid cancer [23] .
In the tissues of thyroid cancers zero or reduced TGFbRII expression has been found compared to benign tumours and normal tissues [1, 26] . In the differentiated and undifferentiated tissues of the thyroid cancers, resistance to TGFb1 coexisted with a reduction in mRNA and protein TGFbRII expression [1, 27] . TGFb1 mRNA expression in PTC cells was higher compared to the surrounding tissues, while the TGFbRII was lower. An inverse correlation between TGFbRII and tumour size was found, and there was no such correlation with respect to TGFb1, which suggests that primarily TGFbRII plays a role in the pathogenesis of PTC [1, 28] . Metastatic thyroid cancer can also be characterised by a decreased sensitivity to the action of TGFb1 [29] . In human PTC, higher expression levels of TGFb1 were closely related with lymph node metastasis, whereas Smad3 expression increased significantly with advanced tumour stages. These findings suggest that the activation of TGFb/Smad3 pathways in cancer cells influences tumour growth [30] . The ability to inhibit tumour growth via TGFbRII, and the discovery of factors inducing the expression of this receptor in tumour cells, may be relevant to the treatment of malignant disease [1] .
The application of molecular analysis of gene expression to clinical tissue samples represents one of the most exciting new areas in "translational" thyroid cancer research. Current data suggest that molecular diagnostic assays may improve the sensitivity and accuracy of FNAB of thyroid nodules and lesions, metastases, and detection of recurrent disease in peripheral blood samples [31] . Specified mRNA's TGFb1 system expression and interactions among the system subunits identified in neoplastic tumour different than in other tissues may be considered in the context of improving PTC diagnostics. On the one hand, thyroid nodules and lesions being one of the commonest clinical situations rarely prove to be malignant, and on the other hand the diagnostic accuracy of FNAB is limited. FNAB is a highly sensitive method in the differential diagnosis of thyroid nodules and lesions; however, a large percentage of thyroid FNABs give a considerable proportion of non-diagnostic results, so there is a need to find new tools for more precise preoperative assessment [32] [33] [34] [35] [36] [37] . Patients would benefit from improved preoperative diagnosis, which could reduce the number or extent of surgeries, long-term health costs, and postsurgical complications.
Molecular analysis of gene expression based on RT--qPCR represents new exciting areas of pathophysiology because it creates the opportunity to explore the pathomechanisms occurring in the thyroid gland.
Conclusions
1. Strict regulation observed among transcriptional activity of TGFb1 and their receptor TGFbRI-III genes in control tissues is disturbed in all pathological tissues -it is completely disturbed in papillary cancer and Graves' disease, and partially in non-toxic and toxic nodular goitre. 2. In papillary cancer tissue, higher transcriptional activity of TGFb1 gene and lower transcriptional activity of TGFbRII and TGFbRIII genes in comparison with benign tissues suggests pathogenetic importance of this cytokine and its receptors in cancer development. 3. In Graves' disease tissue, higher transcriptional activity of TGFbRII and TGFbRIII genes in comparison with other pathological tissues indicates a partici- pation of the receptors in the pathomechanism of autoimmune thyroid disease (AITD). 4. TGFb1 blood concentrations rather do not reflect pathological processes taking place in thyroid gland, although in patients with toxic nodular goitre we noted a correlation between TGFb1 concentration in blood and mRNA TGFbRII expression in thyroid, which probably indicates the participation of circulating TGFb1 in the phenomenon of the receptor downregulation.
